Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/243—Platinum; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2217/00—Genetically modified animals
  • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
  • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2227/00—Animals characterised by species
  • A01K2227/10—Mammal
  • A01K2227/105—Murine
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2267/00—Animals characterised by purpose
  • A01K2267/03—Animal model, e.g. for test or diseases
  • A01K2267/0331—Animal model for proliferative diseases
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This disclosure relates to methods of treating cancer, and more particularly, to methods of treating cancer with attenuated Salmonella typhimurium.
• this disclosure relates to methods of treating cancer with Salmonella typhimurium.
• a dose of a chemotherapy agent is administered in combination with a dose of attenuated Salmonella typhimurium.
• the dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent.
• the attenuated Salmonella typhimurium can include a truncated interleukin-2 gene.
• the combination provides a synergistic effect that provides a greater reduction in tumor burden than the administration of an equivalent dose of the chemotherapy agent alone. As a result, a lower and less toxic dose of the chemotherapy agent can be used, which provides effective treatment while minimizing side effects caused by the toxicity of the chemotherapy agent.
• a method of treating cancer includes administering a combination of a dose of a chemotherapy agent and a dose of a composition consisting essentially of attenuated Salmonella typhimurium.
• the dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent.
• the combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
• the toxicity of the combination is lower than the toxicity of the maximum effective dose of the chemotherapy agent.
• a method of treating cancer includes administering a combination of a dose of a chemotherapy agent and a dose of attenuated Salmonella typhimurium containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO: 2.
• the dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent.
• the combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the attenuated Salmonella typhimurium containing the plasmid carrying the coding sequence encoding the truncated human interleukin-2.
• the toxicity of the combination is lower than the toxicity of the maximum effective dose of the chemotherapy agent.
• an anti-tumor agent for use in a method of treating cancer includes a combination of a dose of a chemotherapy agent and a dose of a composition consisting essentially of attenuated Salmonella typhimurium.
• the method includes administering the combination of the dose of the chemotherapy agent and the dose of the composition consisting essentially of attenuated Salmonella typhimurium.
• the dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent.
• the combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
• the toxicity of the combination is lower than the toxicity of the maximum effective dose of the chemotherapy agent.
• an anti-tumor agent for use in a method of treating cancer includes a combination of a dose of a chemotherapy agent and a dose of attenuated Salmonella typhimurium containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO: 2.
• the method includes administering the dose of the chemotherapy agent in combination with the dose of attenuated Salmonella typhimurium containing the plasmid carrying the coding sequence encoding the truncated human interleukin-2.
• the dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent.
• the combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the attenuated Salmonella typhimurium containing the plasmid carrying the coding sequence encoding the truncated human interleukin-2.
• the toxicity of the combination is lower than the toxicity of the maximum effective dose of the chemotherapy agent.
• FIG. 1 A shows the pIL2 plasmid containing the coding sequence encoding the human interleukin-2 protein, used to construct SalpIL2, attenuated S. typhimurium with the IL-2 gene.
• FIG. IB shows the pNG. l plasmid without the coding sequence encoding the human interleukin-2 protein, used to construct SalpNG. l, attenuated S. typhimurium without the IL-2 gene.
• FIG. 2 is a flow diagram of a method of treating cancer with a combination of attenuated S. typhimurium and a chemotherapy agent according to various embodiments.
• FIG. 3 is a line graph of single tumor burden versus days post-treatment in mice treated with combinations of attenuated S. typhimurium and doxorubicin compared to control groups.
• FIG. 4 is a line graph of single tumor burden versus days post-treatment in mice treated with a combination of SalpIL2 and doxorubicin compared to control groups.
• FIG. 5 is a line graph of single tumor burden versus days post-treatment in mice treated with combinations of SalpNG.1 and doxorubicin compared to control groups.
• FIG. 6 is a line graph of percent weight change versus days post-treatment in mice treated with combinations of attenuated S. typhimurium and doxorubicin compared to control groups.
• Bacttenuated means bacteria selected or altered to greatly diminish its capacity to cause disease, but still able to retain its ability to colonize the gut associated lymphoid tissue.
• Coding sequence and "coding region,” as used herein, are used interchangeably and refer to a polynucleotide that encodes a protein and, when placed under the control of appropriate regulatory sequences, expresses the encoded protein.
• the boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end.
• IL-2 means the protein human interleukin-2.
• NK or "NK cell,” as used herein, means natural killer cell.
• operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
• a regulator sequence is operably linked to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory sequence.
• regulatory Sequence refers to a nucleotide sequence that regulates expression of a coding region to which it is operably linked.
• Non-limiting examples of regulatory sequences include promoters, transcription initiation sites, translation start sites, translation stop sites and terminators.
• Attenuated Salmonella typhimurium has been developed as a vector to deliver therapeutic agents to tumors.
• the potential of S. typhimurium is largely due to its reported propensity to accumulate at greater than 1,000-fold higher concentration in tumors relative to healthy tissues.
• the genetic manipulability of S. typhimurium allows for the expression of foreign recombinant proteins, making these bacteria an effective delivery system for proteins that may be toxic when administered systemically.
• Interleukin-2 is a protein naturally produced by the human body which promotes lymphocyte proliferation and enhances the cytolytic function of T cells and natural killer (NK) cells. It is thus able to stimulate the immune system to produce cancer-destroying white blood cells.
• IL-2 based immunotherapy in certain types of cancer has been studied for years with limited success.
• the amino acid sequence (SEQ ID NO: 3) of the normal human IL-2 protein encoded by SEQ ID NO: 4 (the DNA sequence encoding normal human IL-2) is shown in FIG. 3 of U.S. patent application Ser. No. 13/524,503 now U.S. Pat. No. 8,647,618, which is a continuation of U.S. patent application Ser. No.
• IL-2 is naturally produced by the human body, its maximum effectiveness requires a higher concentration and more specific delivery vector to the disease site.
• S. typhimurium is used due to its natural ability to colonize the gut associated lymphoid tissue (GALT), liver and spleen. Colonization of the liver by the attenuated S. typhimurium further initiates a generalized cellular response against the bacteria or can persist as a carrier state.
• GALT gut associated lymphoid tissue
• the ⁇ 4550 strain of S. typhimurium used in the present disclosure contains a gene deletion constructed by transposon mutagenesis with TnlO followed by selection for furasic acid resistance.
• FIG. 1 A shows the pIL2 plasmid containing the coding sequence encoding the human interleukin-2 protein, used to construct SalpIL2, attenuated S. typhimurium with the IL-2 gene.
• standard P22 phage transduction of the mouse virulent S. typhimurium SR-11 strain ⁇ 3306 was employed to construct the ⁇ 4550 strain that lacks the ability to synthesize adenylate cyclase and the cAMP receptor protein (CRP).
• Cyclic AMP and cAMP receptor protein are necessary for the transcription of many genes and operons concerned with the transport and breakdown of catabolites.
• cAMP is found in mammalian tissue and theoretically could be used by the bacteria to increase the potential for virulence, the lack of a cAMP receptor protein should abolish any benefit that could occur by the uptake of cAMP by these mutant bacteria.
• a synthetic cDNA (SEQ ID NO: 5), coding for a truncated human IL-2 protein, optimized for expression in Escherichia coli was inserted into plasmid pYA292 using well known methods.
• the truncated cDNA (SEQ ID NO: 1) is a part of the synthetic IL-2 nucleotide sequence (SEQ ID NO: 5). This sequence is one nucleotide short of the sequence that was intended to code for a full-length mature human IL-2 protein.
• “mature” means a protein lacking the beginning (N-terminal) 20 amino acid signal sequence that is cleaved off as the molecule is secreted from the a human cell.
• the mutation that occurred is a deletion of a "t" nucleotide between the "a” at position 272 and the "g” at position 273. This resulted in an in-frame taa stop codon at position 274 that truncated the resultant IL-2 protein.
• the resulting DNA nucleotide sequence is SEQ ID NO: 1 and the expressed protein is SEQ ID NO: 2.
• the IL-2 gene fragment was ligated into the pYA292 vector using T4 DNA ligase (Promega, Madison, Wis.) with a 3: 1 molar excess of insert and incubating for 4 hours at 16 °C.
• the ligation mix was then electroporated into the ⁇ 4550 strain of attenuated S. typhimurium.
• S. typhimurium, Acya-l Acrp-l AasdAl strain ⁇ 4550 was grown in Luria Broth (Sigma, St. Louis, Mo.) containing 50 mg/ml diaminopimelic acid (DAP).
• FIG. IB shows the pNG. l plasmid without the coding sequence encoding the human interleukin-2 protein, which is used to construct SalpNG. l, attenuated S. typhimurium without the IL-2 gene.
• SalpNG.1 was constructed by transforming ⁇ 4550 with pNG 1, a plasmid containing cDNA coding for aspartate semialdehyde dehydrogenase to complement the ⁇ 4550 requirement for diaminopimelic acid.
• plasmid pYA292 was cut with EcoRI and Hindlll, the ends filled in, and the plasmid recircularized to eliminate the LacZ(alpha) coding sequence.
• SalpNG. l Overnight cultures of SalpNG. l were grown in lysogeny broth (LB) and flash frozen with liquid nitrogen in 15% glycerol in LB and stored at -80°C. Before treatment, bacteria were thawed at 37°C and appropriately diluted in phosphate-buffered normal saline (PBS). The difference between SalpNG. l and SalpIL2 is the presence of the truncated human IL-2 gene.
• PBS phosphate-buffered normal saline
• FIG. 2 is a flow diagram of method 200.
• Method 200 is a method of treating cancer with a combination of attenuated S. typhimurium and a chemotherapy agent according to various embodiments.
• Method 200 includes administering a first dose of attenuated S.
• Method 200 need not include all of the steps shown in FIG. 2.
• method 120 may exclude the steps of administering a second dose of attenuated S. typhimurium (202) and administering a third dose of attenuated S. typhimurium (204).
• method 200 can include additional steps, such as administering a fourth dose of attenuated S. typhimurium and/or administering a fourth dose of the chemotherapy agent.
• the number of doses of attenuated S. typhimurium and the chemotherapy agent in method 200 can be varied depending on the organism and the type of cancer being treated.
• method 200 includes administering a first dose of attenuated S. typhimurium and a first dose of a chemotherapy agent (201) on a first day, administering a second dose of a chemotherapy agent (203) on a second day a week after the first day, and administering a third dose of a chemotherapy agent (205) on a third day a week after the second day.
• a single dose of attenuated S. typhimurium is administered throughout the entire treatment period.
• method 200 includes administering a first dose of attenuated S. typhimurium and a first dose of a chemotherapy agent (201) on a first day, administering a second dose of attenuated S.
• typhimurium (202) on a second day a week after the first day, administering a second dose of a chemotherapy agent (203) on the second day a week after the first day, and administering a third dose of a chemotherapy agent (205) on a third day a week after the second day.
• two doses of attenuated S. typhimurium are administered throughout the entire treatment period.
• method 200 includes administering a first dose of attenuated S. typhimurium and a first dose of a chemotherapy agent (201) on a first day, administering a second dose of attenuated S. typhimurium (202) on a second day three weeks after the first day, administering a second dose of a chemotherapy agent (203) on the second day three weeks after the first day, administering a third dose of attenuated S. typhimurium (204) on a third day three weeks after the second day, and administering a third dose of a chemotherapy agent (205) on the third day three weeks after the second day.
• This embodiment further includes administering a fourth dose of attenuated S.
• administering the first dose of attenuated S. typhimurium (201) includes orally or intravenously administering the attenuated S. typhimurium.
• administering a first dose of attenuated S. typhimurium (201) includes administering a oral dose of SalpIL2.
• the dose is about 1 x 10 9 cfu.
• administering a first dose of attenuated S. typhimurium (201) includes administering a intravenous (IV) dose of SalpNG.1.
• the dose is about 2 x l0 6 cfu.
• administering a first dose of a chemotherapy agent (201) includes administering a IV dose of doxorubicin.
• the dose of doxorubicin is 1.25 mg/kg.
• the dose of doxorubicin is 2.5 mg/kg.
• the chemotherapy agent can be carboplatin, cisplatin, cyclophosphamide, daunorubicin, oxaliplatin, 5-fluorouracil, gemcitabine, or any other appropriate chemotherapy agent.
• Method 200 is advantageous, because the combination provides a synergistic effect that provides a greater reduction in tumor burden than the administration of the chemotherapy agent alone. As a result, a lower and less toxic dose of the chemotherapy agent can be used, which provides effective treatment while minimizing side effects caused by the toxicity of the chemotherapy agent.
• the BALB-neuT model is a genetically engineered mouse model in which mammary tumor development is driven by expression of a constitutively activated rat homolog of human epidermal growth factor receptor 2.
• autochthonous tumors develop over several months and are palpable in the mammary pads of female mice around 16 weeks of age.
• the tumors closely resemble the aggressive Her2-driven cancer found in human patients.
• BALB-neuT mice were maintained in specific pathogen free conditions and fed standard mouse chow (Harlan). Animals were cared for by the University of Minnesota's Research Animal Resources, and all animal use was approved by the University's
• mice Female BALB-neu-T mice spontaneously developed palpable mammary fat pad tumors around 16 weeks of age (approximately 50-60mm 3 ). At this time (day 0), the mice typically had 1-3 palpable tumors. For each experiment, individual tumors were measured by caliper, and their volume was calculated. Individual tumor volumes were calculated as spheroid (L x W 2 x 0.52) and combined to give a total tumor burden measurement for each mouse. Tumor burden data was gathered weekly from day 0 to day 35. Additionally, percent weight change data was gathered weekly for each mouse from day 0 to day 35. The percent weight change was calculated based on the baseline weight of each mouse.
• S. typhimurium and the chemotherapy agent doxorubicin.
• a prescribed amount per cfu of the appropriate S. typhimurium strain (SalpIL2 or SalpNG. l) was administered via intravenous injection or gavage orally in 100 of PBS.
• the doxorubicin was administered
• control groups received PBS alone, doxorubicin alone, SalpIL2 alone, or
• One control group (301) received PBS alone.
• the tumors in the mice enlarged over time, and new tumors appeared on the remaining fat pads, usually until each mammary pad developed a tumor.
• average total tumor burden per mouse reached 5.66 cm 3 by day 35, at which point the mice were moribund and euthanized.
• mice received SalpIL2 alone. This control group received an oral dose of lxlO 9 cfu SalpIL2 on day 0 and did not receive any additional SalpIL2 or doxorubicin treatments.
• Another control group (306) received Salp NG. l alone. This control group received an IV dose of 2xl0 6 cfu SalpNG. l on day 0 and did not receive any additional SalpNG.1 or doxorubicin treatments.
• mice (307) received an oral dose of lxl 0 9 cfu SalpIL2 as well as IV 1.25 mg/kg doxorubicin on day 0. Two additional doses of IV 1.25 mg/kg doxorubicin were administered on days 7 and 14.
• a first group of mice (308) received an IV dose of 2x10 6 cfu SalpNG. l as well as IV 1.25 mg/kg doxorubicin on day 0.
• Two additional doses of IV 1.25 mg/kg doxorubicin were administered on days 7 and 14.
• a second group of mice (309) received an IV dose of 2xl0 6 cfu SalpNG. l as well as IV 2.5 mg/kg doxorubicin on day 0.
• Two additional doses of IV 2.5 mg/kg doxorubicin were administered on days 7 and 14.
• FIGS. 3-6 show the results of tumor treatment in the BALB-neuT model using combinations of attenuated S. typhimurium and the chemotherapy agent doxorubicin as compared to a number of control groups that received PBS alone, doxorubicin alone, SalpIL2 alone, or SalpNG.1 alone.
• the data shown includes day 0, on which the first treatment was administered, day 14 on which a second treatment was administered, and day 21, on which a third treatment was administered. Subsequent data points were taken post-treatment on days 28 and 35.
• FIG. 3 is a line graph of single tumor burden versus days post-treatment in mice treated with combinations of attenuated S. typhimurium and doxorubicin compared to control groups.
• the mice did not survive or were moribund and euthanized by day 30 or 35.
• the tumor burden was the lowest and remained around 100 mm 3 at day 35.
• FIG. 4 is a line graph of single tumor burden versus days post-treatment in mice treated with a combination of SalpIL2 and doxorubicin compared to control groups.
• the mice did not survive or were moribund and euthanized by day 30 or 35.
• a statistically significant reduction in tumor burden is shown in the group that received a combination of a single oral dose of SalpIL2 and 1.25 mg/kg doxorubicin (307) as compared to the control group that received only a single oral dose of SalpIL2.
• the tumor burden of the control group that received a single oral dose of SalpIL2 (305) was double that of the group that received the combination of SalpIL2 and 1.25 mg/kg doxorubicin (307) by day 35. This further demonstrates the synergistic effect of the combination treatment of oral SalpIL2 and 1.25 mg/kg doxorubicin.
• FIG. 5 is a line graph of single tumor burden versus days post-treatment in mice treated with combinations of SalpNG.1 and doxorubicin compared to control groups.
• the mice did not survive or were moribund and euthanized by day 30 or 35.
• the tumor burden was the lowest and remained around 100 mm 3 at day 35.
• the control group that received 25% of the MTD of doxorubicin i.e.
• the tumor burden was almost double that of the group that received the MTD of doxorubicin by day 21, and almost 5 times as high by day 35.
• the tumor burden was in between that of the control group that received the MTD of doxorubicin (302) and the group that received 1.25 mg/kg of doxorubicin (304).
• FIG. 6 is a line graph of percent weight change versus days post-treatment in mice treated with combinations of attenuated S. typhimurium and doxorubicin compared to control groups.
• Weight change in mice is an accurate measure of the degree of toxicity of a chemotherapy agent. Significant weight loss translates to significant toxicity. While the control group that received PBS (301) saw a greater than 25% increase in weight by day 30, the mice in that group died or were moribund and euthanized due to tumor growth.
• the control group that received the MTD dose of 5 mg/kg of doxorubicin (302) showed a significant reduction in weight, with a loss of greater than 20% by day 14 and almost 10% by day 35.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Microbiology (AREA)
• Inorganic Chemistry (AREA)
• Mycology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=62492129

Family Applications (1)

Country Status (4)

Cited By (7)

Citations (1)

Family Cites Families (16)

• 2017
  • 2017-12-06 WO PCT/US2017/064813 patent/WO2018106754A1/en not_active Ceased
  • 2017-12-06 JP JP2019531255A patent/JP7249279B2/ja active Active
  • 2017-12-06 US US16/467,338 patent/US11576936B2/en active Active
  • 2017-12-06 EP EP17877671.2A patent/EP3550976A4/en active Pending
• 2022
  • 2022-09-09 JP JP2022143644A patent/JP2022171776A/ja active Pending
• 2023
  • 2023-01-26 US US18/159,934 patent/US12090179B2/en active Active
• 2024
  • 2024-08-28 US US18/817,472 patent/US20240415898A1/en active Pending

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events